Infibeam Avenues Ltd
NSE:INFIBEAM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
20
40.15
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Infibeam Avenues Ltd
Total Liabilities & Equity
Infibeam Avenues Ltd
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Infibeam Avenues Ltd
NSE:INFIBEAM
|
Total Liabilities & Equity
â‚ą52.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
WNS (Holdings) Ltd
NYSE:WNS
|
Total Liabilities & Equity
$1.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
One 97 Communications Ltd
NSE:PAYTM
|
Total Liabilities & Equity
â‚ą171.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Eclerx Services Ltd
NSE:ECLERX
|
Total Liabilities & Equity
â‚ą29.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
Computer Age Management Services Ltd
NSE:CAMS
|
Total Liabilities & Equity
â‚ą14.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Firstsource Solutions Ltd
NSE:FSL
|
Total Liabilities & Equity
â‚ą74B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
See Also
What is Infibeam Avenues Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
52.2B
INR
Based on the financial report for Jun 30, 2024, Infibeam Avenues Ltd's Total Liabilities & Equity amounts to 52.2B INR.
What is Infibeam Avenues Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
12%
Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for Infibeam Avenues Ltd have been 14% over the past three years , 12% over the past five years .